全文获取类型
收费全文 | 258502篇 |
免费 | 23317篇 |
国内免费 | 5955篇 |
专业分类
耳鼻咽喉 | 3783篇 |
儿科学 | 4880篇 |
妇产科学 | 4418篇 |
基础医学 | 18703篇 |
口腔科学 | 8411篇 |
临床医学 | 29003篇 |
内科学 | 24944篇 |
皮肤病学 | 3008篇 |
神经病学 | 12444篇 |
特种医学 | 6883篇 |
外国民族医学 | 16篇 |
外科学 | 24149篇 |
综合类 | 39759篇 |
现状与发展 | 10篇 |
一般理论 | 27篇 |
预防医学 | 37646篇 |
眼科学 | 2730篇 |
药学 | 24627篇 |
538篇 | |
中国医学 | 30104篇 |
肿瘤学 | 11691篇 |
出版年
2024年 | 1230篇 |
2023年 | 5456篇 |
2022年 | 9825篇 |
2021年 | 13065篇 |
2020年 | 12956篇 |
2019年 | 13690篇 |
2018年 | 12205篇 |
2017年 | 11059篇 |
2016年 | 10052篇 |
2015年 | 9435篇 |
2014年 | 18041篇 |
2013年 | 18519篇 |
2012年 | 16010篇 |
2011年 | 16822篇 |
2010年 | 13434篇 |
2009年 | 11864篇 |
2008年 | 11149篇 |
2007年 | 11081篇 |
2006年 | 9594篇 |
2005年 | 7963篇 |
2004年 | 6608篇 |
2003年 | 5780篇 |
2002年 | 4473篇 |
2001年 | 3699篇 |
2000年 | 3181篇 |
1999年 | 2583篇 |
1998年 | 2044篇 |
1997年 | 1849篇 |
1996年 | 1498篇 |
1995年 | 1426篇 |
1994年 | 1259篇 |
1993年 | 1117篇 |
1992年 | 1016篇 |
1991年 | 878篇 |
1990年 | 760篇 |
1989年 | 738篇 |
1988年 | 673篇 |
1987年 | 605篇 |
1986年 | 535篇 |
1985年 | 1802篇 |
1984年 | 2079篇 |
1983年 | 1299篇 |
1982年 | 1722篇 |
1981年 | 1196篇 |
1980年 | 1017篇 |
1979年 | 909篇 |
1978年 | 739篇 |
1977年 | 553篇 |
1976年 | 695篇 |
1975年 | 478篇 |
排序方式: 共有10000条查询结果,搜索用时 2 毫秒
1.
《Journal of vascular and interventional radiology : JVIR》2021,32(10):1449-1456
PurposeTo investigate the safety and efficacy of thyroid artery embolization (TAE) in the treatment of nodular goiter (NG).MethodsDuring a 5.5-year period, 56 consecutive patients with a NG underwent TAE. In Group A, there were 20 patients with a solitary/dominant 5–11-cm nodule, and in Group B, there were 36 patients with numerous nodules. Of the 56 patients, 47 (84%) had a retrosternal goiter and 25 had hyperthyroidism. In all patients, clinical and radiological evaluations were made at baseline and 6 months after TAE, and these parameters were statistically compared.ResultsIn 56 patients, 145 of the 146 thyroid arteries were successfully embolized. The 30-day mortality rate was 1.8%. Minor and major complications occurred in 25 and 2 patients, respectively. Six months after the TAE, the mean nodule volume was reduced from 80.2 mL to 25.0 mL, the mean thyroid volume was reduced from 147.0 mL to 62.6 mL, and the mean intrathoracic extension was reduced from 31.7 mm to 15.9 mm (P < .001). Of the 22 patients with non–Graves hyperthyroidism, 19 (86%) became euthyroid. The mean thyroid-related patient-reported outcome scores improved from 155.4 to 70.4 (P < .001). Of the 51 patients, 50 (98%) declared that they would recommend TAE to other patients with NG.ConclusionsTAE is safe and effective for the treatment of NG, with a significant volume reduction of the nodule(s) and thyroid gland. 相似文献
2.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
3.
4.
中药生产过程质量控制关键技术研究进展 总被引:10,自引:8,他引:2
中医药发展已上升到国家战略层面,在医药行业贯彻实施"中国制造2025"战略的新形势下,中药生产过程质量控制是中药工业需要加快突破的关键领域之一。对中药生产过程质量控制领域在工艺设计、分析检测、过程建模、制造装备等方面的关键共性问题进行解析,综述了中药生产过程质量控制体系中工艺过程理解、生产过程实时分析方法开发、过程控制策略建立3个方面的研究进展;并结合企业研究实践,介绍了质量源于设计(quality by design,Qb D)、过程分析技术(process analytical technology,PAT)、实验设计(design of experiment,DOE)、多变量统计分析等关键技术在上述3个研究方向中的应用进展,分析了实际工业应用的难点问题并对其应用前景进行展望,旨在为中药企业应用和提升生产过程质量控制技术提供参考。 相似文献
5.
通过对中医古籍中有关升降散论述的文献梳理,全面探讨其内涵。本方是在大黄、僵蚕为雏形的基础上增加蝉蜕、姜黄而成方,几经易名,终在杨璿《伤寒瘟疫条辨》中为后人所熟知。本方广泛用于治疗瘟疫,以丸剂、散剂为主,方便携带,便于服用;重用大黄旨在祛邪、逐秽;应用时视人之体质强弱和量其毒之轻重而判断用药多寡,并辅以米酒、生蜜等以顾护正气。杨璿将其由治疗“热疫”的专方扩展为治疗“表里三焦大热”的通用方剂,扩大了本方治疗疾病范围。 相似文献
6.
严桂英 《中国卫生标准管理》2020,(8):95-98
目的探究益气养精法对老年肺癌患者肿瘤标志物、生存期影响。方法研究纳入60例老年肺癌患者,均由本院2016年1月-2017年1月收治,采取随机数字表法将患者分为两组,对照组患者(30例)常规化疗治疗,观察组患者(30例)在化疗基础上联合益气养精法治疗,比较两组患者治疗效果、治疗前后癌胚抗原(carcino-embryonic antigen,CEA)及血清癌抗原125(serum oncoantigen 125,CA 125)肿瘤标志物水平、不良反应情况及患者2年生存率。结果观察组患治疗有效率高于对照组,P<0.05;治疗前,两组患者CEA及CA 125水平相当,P>0.05,治疗后均改善,观察组优于对照组,P<0.05;观察组患者不良反应与对照组相当,均较低,P>0.05;观察组患者2年生存率高于对照组,P<0.05。结论益气养精法治疗老年肺癌患者效果患者,患者症状改善,不良反应少,安全可靠,且患者2年生存率较高。 相似文献
7.
8.
9.
《Archives of Cardiovascular Diseases》2022,115(10):505-513
Central illustration: cumulative major adverse cardiac events (MACE) and bioresorbable vascular scaffold (BVS) thrombosis rates after 1, 2, 3, 4 and 5 years. 相似文献
10.
Quality of life in stroke survivor–caregiver dyads: a new conceptual framework and longitudinal study protocol 下载免费PDF全文